Advertisement

Clinical Drug Investigation

, Volume 30, Issue 10, pp 707–710 | Cite as

Aripiprazole as an Augmentation Agent in Treatment-Resistant Body Dysmorphic Disorder

  • Özcan Uzun
  • Barbaros Özdemir
Case Report

Abstract

Body dysmorphic disorder (BDD) is a relatively common and severe disorder for which pharmacotherapy has been only minimally studied. BDD often appears to respond to selective serotonin reuptake inhibitors (SSRIs), but many patients do not respond or respond only partially. Investigation of SSRI augmentation strategies is therefore needed. We report a case of treatment-resistant BDD that was successfully treated with pharmacological augmentation of fluvoxamine with aripiprazole. The patient, a 43-year-old woman, had been taking a stable dose of fluvoxamine (400 mg/day) for 6 months when she was started on aripiprazole (10 mg/day). After 10 weeks of this treatment, her clinical condition improved markedly, as indicated by a significant decrease in the Body Dysmorphic Disorder Examination score. This case presents some preliminary evidence that addition of the atypical antipsychotic agent aripiprazole may be useful in patients with treatment-resistant BDD. However, results from controlled studies are needed to support this finding.

Keywords

Aripiprazole Fluvoxamine Pimozide Body Dysmorphic Disorder Augmentation Strategy 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Notes

Acknowledgements

No sources of funding were used to assist in the preparation of this report. The authors have no conflicts of interest that are directly relevant to the content of this report.

References

  1. 1.
    American Psychiatric Association Committee on Nomenclature and Statistics. Diagnostic and statistical manual of mental disorders. 4th ed. Washington, DC: American Psychiatric Association, text revision, 2000Google Scholar
  2. 2.
    Bohne A, Keuthen NJ, Wilhelm S, et al. Prevalence of symptoms of body dysmorphic disorder and its correlates: a cross-cultural comparison.Psychosomatics 2002; 43:486–90PubMedCrossRefGoogle Scholar
  3. 3.
    Phillips KA. The broken mirror: understanding and treating body dysmorphic disorder. New York: Oxford University Press, 1996: 162–4Google Scholar
  4. 4.
    Craven JL, Rodin GM.Cyproheptadine dependence associated with an atypical somatoform disorder? Can J Psychiatry 1987;32:143–5Google Scholar
  5. 5.
    Barr LC, Goodman WK, Price LH. Acute exacerbation of body dysmorphic disorder during tryptophan depletion. Am J Psychiatry 1992; 149: 1406–7PubMedGoogle Scholar
  6. 6.
    Phillips KA, Albertini RS, Siniscalchi JM, et al. Effectiveness of pharmacotherapy for body dysmorphic disorder: a chart-review study. J Clin Psychiatry 2001; 62: 721–7PubMedCrossRefGoogle Scholar
  7. 7.
    Phillips KA. Treating body dysmorphic disorder using medication. Psychiatr Ann 2004; 34: 945–53Google Scholar
  8. 8.
    First MB, Spitzer RL, Williams JBW. Structured clinical interview for DSM-IV (SCID). Washington, DC: American Psychiatric Association, 1997Google Scholar
  9. 9.
    Corapcioglu A, Aydemir O, Yildiz M, et al. Structured clinical interview for DSM IV (SCID), Turkish version. Ankara: Hekimler Yayin Birligi, 1999Google Scholar
  10. 10.
    Rosen JC, Reiter J. Development of the body dysmorphic disorder examination. Behav Res Ther 1996; 34: 755–66PubMedCrossRefGoogle Scholar
  11. 11.
    Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry 1960; 23: 56–62PubMedCrossRefGoogle Scholar
  12. 12.
    Saxena S, Winograd A, Dunkin JJ,et al. A retrospective review of clinical characteristics and treatment response in body dysmorphic disorder versus obsessive-compulsive disorder. J Clin Psychiatry 2001; 62: 67–72PubMedCrossRefGoogle Scholar
  13. 13.
    NCCMH, National Collaborating Centre for Mental Health. Core interventions in the treatment of obsessive compulsive disorder and body dysmorphic disorder. London: British Psychiatric Society and Royal College of Psychiatrists, 2006Google Scholar
  14. 14.
    Cassano GB, Fagiolini A, Lattanzi L, et al. Aripiprazole in the treatment of schizophrenia. Clin Drug Investig 2007; 27:1–13PubMedCrossRefGoogle Scholar
  15. 15.
    Citrome L. A review of aripiprazole in the treatment of patients with schizophrenia or bipolar I disorder. Neuro-psychiatr Dis Treat 2006; 2: 427–43CrossRefGoogle Scholar
  16. 16.
    Sarkar R, Klein J, Krüger S. Aripiprazole augmentation in treatment-refractory obsessive-compulsive disorder. Psycho-pharmacology 2008; 197: 687–8Google Scholar
  17. 17.
    Phillips KA, Pinto A, Menard W, et al. Obsessive-compulsive disorder versus body dysmorphic disorder: a comparison study of two possibly related disorders. Depress Anxiety 2007; 24: 399–409PubMedCrossRefGoogle Scholar
  18. 18.
    Hadley S, Newcorn J, Hollander E. The neurobiology and psychopharmacology of body dysmorphic disorder. In: Castle D, Phillips K, editors. Disorders of body image. Petersfield: Wrightson Biomedical Publishing Ltd, 2002: 139–55Google Scholar
  19. 19.
    Hollander E, Wong C. Introduction: obsessive-compulsive spectrum disorders. J Clin Psychiatry 1995; 56: 3–6PubMedGoogle Scholar
  20. 20.
    Goodman WK, McDougle CJ, Price LH. The role of serotonin and dopamine in the pathophysiology of obsessive compulsive disorder. Int Clin Psychopharmacol 1992; 7Suppl. 1: 35–8PubMedCrossRefGoogle Scholar
  21. 21.
    Bloch MH, Landeros-Weisenberger A, Kelmendi B, et al. A systematic review: antipsychotic augmentation with treatment refractory obsessive-compulsive disorder. Mol Psychiatry 2006; 11(7): 622–32PubMedCrossRefGoogle Scholar
  22. 22.
    Goodman WK, McDougle CJ, Price LH, et al. Behind the serotonin hypothesis: a role for dopamine in some forms of obsessive compulsive disorder? J Clin Psychiatry 1990; 51: 36–43PubMedGoogle Scholar
  23. 23.
    Phillips KA. Pharmacologic treatment of body dysmorphic disorder: review of the evidence and a recommended treatment approach. CNS Spectrums 2002; 7: 453–63PubMedGoogle Scholar
  24. 24.
    Phillips KA, Dwight MM, McElroy SL. Efficacy and safety of fluvoxamine in body dysmorphic disorder. J Clin Psychiatry 1998; 59: 165–71PubMedCrossRefGoogle Scholar
  25. 25.
    Perugi G, Giannotti D, Di Vaio S, et al. Fluvoxamine in the treatment of body dysmorphic disorder (dysmorphophobia). Int Clin Psychopharmacol 1996; 11: 247–54PubMedCrossRefGoogle Scholar
  26. 26.
    Phillips KA. A placebo-controlled study of pimozide augmentation of fluoxetine in body dysmorphic disorder. Am J Psychiatry 2005; 162: 377–9PubMedCrossRefGoogle Scholar
  27. 27.
    Phillips KA, McElroy SL, Keck Jr PE, et al. A comparison of delusional and nondelusional body dysmorphic disorder in 100 cases. Psychopharmacol Bull 1994; 30: 179–86PubMedGoogle Scholar
  28. 28.
    Phillips KA. Olanzapine augmentation of fluoxetine in body dysmorphic disorder. Am J Psychiatry 2005; 162: 1022–3PubMedCrossRefGoogle Scholar
  29. 29.
    Shapiro DA, Renock S, Arrington E, et al. Aripiprazole, a novel atypical antipsychotic drug with a unique and robust pharmacology. Neuropsychopharmacology 2003; 28: 1400–11PubMedCrossRefGoogle Scholar

Copyright information

© Adis Data Information BV 2010

Authors and Affiliations

  1. 1.Department of PsychiatryGulhane School of MedicineEtlikTurkey

Personalised recommendations